Correction (DOI:10.1016/j.jaci.2007.02.022);Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 119, Issue 6, 2007, Pages 1430-1437

  Kaiser, Harold B ^a   Naclerio, Robert M ^b   Given, John ^c   Toler, Tom N ^d   Ellsworth, Anna ^d   Philpot, Edward E ^d  

^a Clinical Research Institute   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c GlaxoSmithKline ^*

^d GLAXOSMITHKLINE   (United States)

Author keywords

fluticasone furoate; Intranasal corticosteroids; ragweed pollen; seasonal allergic rhinitis

Indexed keywords

FLUTICASONE FUROATE; PLACEBO; UNCLASSIFIED DRUG; USAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; EYE BURNING; FEMALE; HAY FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASAL PRURITUS; NOSE CONGESTION; OCULAR PRURITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SNEEZING;

EID: 34249820777     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.04.001     Document Type: Erratum

References (32)

1. Frieri M. Inflammatory issues in allergic rhinitis and asthma. Allergy Asthma Proc 26 (2005) 163-169
2. Baroody F.M. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol Head Neck Surg 128 (2003) 616-631
3. Schoenwetter W.F., Dupclay Jr. L., Appajosyula S., Botteman M.F., and Pashos C.L. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 20 (2004) 305-317
4. Thompson A.K., Juniper E., and Meltzer E.O. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 85 (2000) 338-347
5. Spangler D.L., Abelson M.B., Ober A., and Gotnes P.J. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 25 (2003) 2245-2267
6. Bousquet J., van Cauwenberge P., and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 suppl (2001) S147-S334
7. Dykewicz M.S., Fineman S., Skoner D.P., Nicklas R., Lee R., Blessing-Moore J., et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81 suppl (1998) 478-518
8. Allergies in America: executive summary. Available at: http://www.myallergiesinamerica.com. Accessed July 17, 2006.
9. van Cauwenberge P., Bachert C., Passalacqua G., Bousquet J., Canonica G.W., Durham S.R., et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 55 (2000) 116-134
10. Wilken J.A., Berkowitz R., and Kane R. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 89 (2002) 372-380
11. Frenz D.A. Volumetric ragweed pollen data for eight cities in the continental United States. Ann Allergy Asthma Immunol 82 (1999) 41-46
12. Gadermaier G., Dedic A., Obermeyer G., Frank S., Himly M., and Ferreira F. Biology of weed pollen allergens. Curr Allergy Asthma Rep 4 (2004) 391-400
13. Banken R., and Comtois P. [Concentration of ragweed pollen and prevalence of allergic rhinitis in 2 municipalities in the Laurentides]. Allerg Immunol (Paris) 24 (1992) 91-94
14. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 9 (1998) 116-124
15. Wjst M., Dharmage S., Andre E., Norback D., Raherison C., and Villani S. Latitude, birth date and allergy. PLoS Med 2 (2005) e294
16. Mygind N., Nielsen L.P., Hoffmann H.J., Shukla A., Blumberga G., Dahl R., et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 108 suppl (2001) S16-S25
17. Andersson M., Andersson P., and Pipkorn U. Topical glucocorticosteroids and allergen-induced increase in nasal reactivity: relationship between treatment time and inhibitory effect. J Allergy Clin Immunol 82 (1988) 1019-1026
18. Task Force on Allergic Disorders. The allergy report. Vol. 1. Milwaukee (WI): American Academy of Allergy, Asthma and Immunology; 2000.
19. Biggadike K, Bledsoe R, Hassell A, Hughes S, Shewchuk L. GW685698X-enhanced affinity for the glucocorticoid receptor: receptor crystal structure and route of metabolic inactivation. Presented at the European Academy of Allergology and Clinical Immunology; 2006. Abstract 783.
20. Salter M, Biggadike K, Clackers M, Solanke Y, Matthews J, Maschera J, et al. GW685698X-enhanced affinity for the glucocorticoid receptor: cellular and in vivo pharmacology. Presented at the European Academy of Allergology and Clinical Immunology; 2006. Abstract 781.
21. Valotis A, Hogger P. Human receptor kinetics and tissue affinity of the enhanced affinity glucocorticoid GW685698X. Presented at the European Academy of Allergology and Clinical Immunology; 2006. Abstract 780.
22. Martin B, Philpot E, Faris M, Toler T, Wu W. A dose-ranging study to evaluate the efficacy and safety of once daily GW685698X nasal spray in subjects with seasonal allergic rhinitis (SAR). Presented at the European Academy of Allergology and Clinical Immunology; 2006. Abstract 782.
23. Philpot E, Faris M, Toler T, Wu W. Once daily GW685698X nasal spray effectively treats ocular symptoms of seasonal allergic rhinitis (SAR). Presented at the European Academy of Allergology and Clinical Immunology; 2006. Abstract 779.
24. Juniper E.F., and Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21 (1991) 77-83
25. Barney N.P., and Graziano F.M. Allergic and immunologic diseases of the eye. In: Adkinson N.F., Yunginger J.W., and Busse W. (Eds). Middleton's allergy: principles and practice (2003), Mosby, Philadelphia (PA) 1602
26. Weiner J.M., Abramson M.J., and Puy R.M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 317 (1998) 1624-1629
27. Bernstein D.I., Levy A.L., Hampel F.C., Baidoo C.A., Cook C.K., Philpot E.E., et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 34 (2004) 952-957
28. DeWester J., Philpot E.E., Westlund R.E., Cook C.K., and Rickard K.A. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 24 (2003) 331-337
29. Meltzer E.O., Bachert C., Staudinger H., and Gates D. Efficacy of intranasal mometasone furoate for the treatment of ocular symptoms in patients with seasonal allergic rhinitis. Allergy Clin Immunol Int 17 suppl 1 (2005) A709
30. Bousquet J., Bindslev-Jensen C., Canonica G.W., Fokkens W., Kim H., Kowalski M., et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 59 suppl 77 (2004) 4-16
31. Allen A., Down G., Newlands A., Rousell V., and Salmon E. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate* in healthy subjects. Ann Allergy Asthma Immunol 98 suppl 1 (2007) A89
32. Blaiss M.S. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 21 (2000) 7-13